Understanding how abnormal Gas activation affects blood cancer
Official title: Mechanisms and targeting of aberrant Gas activation in myeloid neoplasms
Funded at Icahn School of Medicine at Mount Sinai · NIH-11056848 · Data updated 2026-11-12
This study is looking into the genetic changes that cause blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to help find new treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $677,959 |
| NIH project number | 5R01CA271418-03 |
| Project ID | NIH-11056848 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with acute myeloid leukemia or myelodysplastic syndromes, particularly those with specific genetic mutations.
✕Less likely to help
Patients with other types of leukemia or those without the identified genetic mutations may not benefit from this research.
What this research studies
This research investigates the mechanisms behind myeloid neoplasms, particularly focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). By utilizing advanced techniques like CRISPR gene editing and RNA sequencing, the study aims to identify specific genetic mutations that lead to abnormal cell behavior. The goal is to uncover potential therapeutic targets that could lead to effective treatments for patients suffering from these aggressive blood cancers. Patients may benefit from insights into new treatment strategies based on the genetic underpinnings of their disease.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.
How similar studies have gone: Previous research has shown promise in targeting genetic mutations in blood cancers, indicating that this approach could yield significant advancements.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Papapetrou, Eirini — Icahn School of Medicine at Mount Sinai
- Study coordinator: Papapetrou, Eirini
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.